

Jian-Yong Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5209561/publications.pdf>

Version: 2024-02-01

102
papers

2,865
citations

201385

27
h-index

205818

48
g-index

118
all docs

118
docs citations

118
times ranked

4580
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	0.6	301
2	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. <i>Blood</i> , 2014, 124, 1645-1654.	0.6	232
3	Detection of Translocation t(11;14)(q13;q32) in Mantle Cell Lymphoma by Fluorescence in Situ Hybridization. <i>American Journal of Pathology</i> , 1999, 154, 1449-1452.	1.9	189
4	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. <i>Carcinogenesis</i> , 2012, 33, 1294-1301.	1.3	171
5	The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 66, 1-7.	0.4	86
6	Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. <i>Scientific Reports</i> , 2015, 5, 12168.	1.6	84
7	BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis. <i>FEBS Letters</i> , 2009, 583, 401-406.	1.3	59
8	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. <i>Blood Reviews</i> , 2015, 29, 205-213.	2.8	59
9	Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 6448-6458.	0.8	54
10	Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. <i>Oncotarget</i> , 2015, 6, 5426-5434.	0.8	52
11	Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2008, 32, 1071-1077.	0.4	48
12	Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2008, 32, 1491-1498.	0.4	47
13	Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0125429.	1.1	46
14	Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. <i>Cancer Science</i> , 2012, 103, 875-881.	1.7	44
15	Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2007, 31, 1383-1388.	0.4	43
16	TP53 dysfunction in diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 47-55.	2.0	42
17	Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2011, 128, 2192-2201.	2.3	40
18	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 20520-20531.	0.8	40

#	ARTICLE	IF	CITATIONS
19	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Hematological Oncology</i> , 2019, 37, 392-400.	0.8	39
20	Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: A prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. <i>Leukemia and Lymphoma</i> , 2008, 49, 1887-1892.	0.6	35
21	High <i>CRLF2</i> expression associates with <i>IKZF1</i> dysfunction in adult acute lymphoblastic leukemia without <i>CRLF2</i> rearrangement. <i>Oncotarget</i> , 2016, 7, 49722-49732.	0.8	35
22	Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 3329-3335.	0.6	32
23	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. <i>Cancer Medicine</i> , 2018, 7, 1043-1055.	1.3	32
24	Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 588-594.	0.6	31
25	Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 449-457.	1.2	31
26	The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). <i>Annals of Hematology</i> , 2011, 90, 709-717.	0.8	30
27	Low T3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2018, 143, 466-477.	2.3	30
28	SOX11 expression in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1962-1967.	0.6	29
29	Interphase Fluorescence In Situ Hybridization Detection of Cytogenetic Abnormalities in B-Cell Chronic Lymphocytic Leukemia. <i>International Journal of Hematology</i> , 2007, 85, 430-436.	0.7	28
30	CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2009, 33, 237-243.	0.4	28
31	Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. <i>Translational Research</i> , 2014, 163, 565-577.	2.2	28
32	Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2011, 35, 730-734.	0.4	27
33	Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses. <i>PLoS ONE</i> , 2010, 5, e13186.	1.1	27
34	BAG3: a new therapeutic target of human cancers?. <i>Histology and Histopathology</i> , 2012, 27, 257-61.	0.5	27
35	Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2011, 35, 1060-1065.	0.4	26
36	Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1749-1756.	0.6	24

#	ARTICLE	IF	CITATIONS
37	MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. <i>International Journal of Cancer</i> , 2012, 130, 2054-2061.	2.3	24
38	Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2014, 93, 425-435.	0.8	24
39	Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. <i>Haematologica</i> , 2014, 99, e182-e184.	1.7	23
40	Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigenâ€“Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 830-835.	2.0	22
41	The role of SOX11 in mantle cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 1412-1419.	0.4	21
42	Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 2135-2142.	0.8	21
43	Sâ€“MDM4 <scp>mRNA</scp> overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia. <i>Cancer Science</i> , 2012, 103, 2056-2063.	1.7	20
44	Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 13551-13562.	0.8	20
45	Intermediate prognosis of 6q deletion in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 230-237.	0.6	19
46	MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene. <i>Blood Cancer Journal</i> , 2017, 7, 651.	2.8	19
47	Spectrum and immunophenotyping of 653 patients with Bâ€“cell chronic lymphoproliferative disorders in China: A singleâ€“centre analysis. <i>Hematological Oncology</i> , 2018, 36, 121-127.	0.8	19
48	Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69Âyears old with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2570-2579.	0.6	18
49	Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. <i>International Journal of Hematology</i> , 2009, 90, 205-211.	0.7	17
50	The negative prognostic significance of positive direct antiglobulin test in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1482-1487.	0.6	17
51	TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 50, 72-77.	0.4	17
52	Expression levels of Lyn, Syk, PLCÎ³2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 1165-1170.	0.6	16
53	Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma. <i>Frontiers in Immunology</i> , 2016, 7, 654.	2.2	16
54	High levels of <scp>CD</scp>20 expression predict good prognosis in chronic lymphocytic leukemia. <i>Cancer Science</i> , 2013, 104, 996-1001.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1159-1164.	0.6	15
56	Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course. <i>Leukemia Research</i> , 2018, 66, 8-14.	0.4	15
57	An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (lncRNAs) in Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2019, 9, 200.	1.3	15
58	The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1785-1792.	0.6	14
59	Expression of dominant-negative Ikaros isoforms and associated genetic alterations in Chinese adult patients with leukemia. <i>Annals of Hematology</i> , 2012, 91, 1039-1049.	0.8	13
60	Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Supportive Care in Cancer</i> , 2013, 21, 1265-1271.	1.0	13
61	Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. <i>Leukemia and Lymphoma</i> , 2011, 52, 1003-1009.	0.6	11
62	TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. <i>Medical Oncology</i> , 2012, 29, 2166-2173.	1.2	11
63	Acute myeloid leukemia in four patients with t(8;21) treated with all-trans retinoic acid as a single agent. <i>Leukemia and Lymphoma</i> , 2008, 49, 998-1001.	0.6	10
64	MPL W515L mutation in Chinese patients with myeloproliferative diseases. <i>Leukemia and Lymphoma</i> , 2008, 49, 955-958.	0.6	10
65	Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1011-1017.	1.2	10
66	t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review. <i>Oncology Letters</i> , 2016, 12, 4351-4356.	0.8	10
67	Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status. <i>Cancer Biology and Therapy</i> , 2012, 13, 1522-1528.	1.5	9
68	The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2013, 54, 2712-2719.	0.6	9
69	Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. <i>International Journal of Hematology</i> , 2018, 108, 123-129.	0.7	9
70	An analysis of complex chromosomal aberrations in seven cases of myelodysplastic syndromes by M-FISH and whole chromosome painting. <i>International Journal of Hematology</i> , 2008, 88, 369-373.	0.7	8
71	TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2014, 31, 908.	1.2	8
72	The single nucleotide polymorphism and haplotype analysis of MDR1 in Chinese diffuse large B cell lymphoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 24-28.	2.5	8

#	ARTICLE	IF	CITATIONS
73	A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion. <i>Annals of Hematology</i> , 2018, 97, 1663-1669.	0.8	8
74	98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2020, 9, 999-1007.	1.3	8
75	Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis. <i>Leukemia Research</i> , 2009, 33, 1619-1622.	0.4	7
76	High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 536-540.	0.4	7
77	Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations. <i>Chinese Medical Journal</i> , 2016, 129, 1778-1783.	0.9	7
78	Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. <i>Leukemia Research</i> , 2016, 42, 88-92.	0.4	7
79	<i>NOTCH1</i> mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases. <i>Cancer Medicine</i> , 2018, 7, 1689-1696.	1.3	7
80	Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. <i>Medical Oncology</i> , 2012, 29, 2102-2110.	1.2	6
81	High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: Promising post-remission therapy for acute myeloid leukemia in first complete remission?. <i>Medical Oncology</i> , 2014, 31, 980.	1.2	6
82	Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia. <i>Oncotargets and Therapy</i> , 2016, 9, 797.	1.0	6
83	Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma. <i>Cancer Biomarkers</i> , 2018, 22, 807-813.	0.8	6
84	Association between polymorphism of <i>GLI1</i> gene SNP rs2228226 and chronic lymphocytic leukemia in Chinese population. <i>Medical Oncology</i> , 2014, 31, 294.	1.2	5
85	The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 43-51.	1.5	5
86	Association of marital status with stage and survival in patients with mycosis fungoides: A population-based study. <i>Cancer Medicine</i> , 2021, 10, 7320-7329.	1.3	5
87	<i>MDR1</i> polymorphisms affect the outcome of Chinese multiple myeloma patients. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 743-748.	2.5	4
88	The prognostic role of HBV infection in chronic lymphocytic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1309-1315.	1.2	4
89	Trisomy 8 in two newly diagnosed Chinese patients with chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 79-81.	1.0	3
90	Diabetes Mellitus Is Associated with Inferior Prognosis in Patients with Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis. <i>Cancer Research and Treatment</i> , 2020, 52, 189-206.	1.3	3

#	ARTICLE	IF	CITATIONS
91	The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis. <i>Leukemia Research</i> , 2009, 33, e116-e118.	0.4	2
92	Definition of diseaseâ€ progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. <i>Hematological Oncology</i> , 2018, 36, 656-662.	0.8	2
93	Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia. <i>Chinese Medical Journal</i> , 2019, 132, 525-533.	0.9	2
94	Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia. <i>Translational Oncology</i> , 2021, 14, 101176.	1.7	2
95	Rituximab Combining with Fresh Frozen Plasma for the Treatment of Patients with Refractory Advanced CLL. <i>Blood</i> , 2009, 114, 3450-3450.	0.6	2
96	Overexpression of c-Myc-dependent heterogeneous nuclear ribonucleoprotein A1 promotes proliferation and inhibits apoptosis in NOTCH1-mutated chronic lymphocytic leukemia cells. <i>Chinese Medical Journal</i> , 2022, Publish Ahead of Print, .	0.9	2
97	Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker. <i>Annals of Hematology</i> , 2009, 88, 29-36.	0.8	1
98	Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Cancer Biomarkers</i> , 2013, 12, 169-176.	0.8	1
99	Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies. <i>Current Cancer Drug Targets</i> , 2015, 15, 769-780.	0.8	1
100	Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 7494-8.	0.5	1
101	Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 11235-43.	1.3	1
102	Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial. <i>Blood</i> , 2021, 138, 1385-1385.	0.6	0